uPATCH

uPATCH is pioneering the transition of microneedles from research to practical, lifesaving applications. Operating in the healthcare sector, the company focuses on developing microneedles that are less than 1 mm in size, offering a less intrusive and more effective method of drug administration compared to conventional techniques. This technology allows for self-administration, reducing the need for healthcare professionals and minimizing pain and infection risks. By potentially eliminating the costly cold chain distribution associated with traditional vaccines, uPATCH aims to make healthcare more accessible globally. The business model revolves around patented technology that enables safe and effective self-application of microneedles, targeting both individual consumers and healthcare providers. Revenue is generated through the sale of these microneedle products and related technologies. uPATCH has been recognized for its impact in the Netherlands and has secured funding for further development and feasibility studies.

Keywords: microneedles, self-administration, healthcare, drug delivery, cold chain, accessibility, pain reduction, infection prevention, patented technology, funding.